Blood test may help cancer patients avoid nerve damage from chemo
NCT ID NCT03987555
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times
Summary
This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study involves 22 adults with various solid tumors and uses blood draws and surveys to track drug exposure and symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- paclitaxel
- What this could lead to
- If successful, this could help doctors adjust paclitaxel doses to reduce nerve damage while still effectively treating cancer.
- What could go wrong
- This is a small, early feasibility study with only 22 participants and is currently suspended. It focuses on whether blood monitoring is practical, not on proving it improves outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can sound waves replace the scalpel for breast tumors?
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Could a bank of breast cancer samples unlock new treatments?
- Can a Zinc-Based compound fight cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?